The main predictor of outcomes in herpes simplex virus (HSV) encephalitis (HSE) is the delay between hospital admission and initiation of acyclovir. In this study, factors associated with late initiation of acyclovir were identified. The study included adults from northern France whose cerebrospinal fluid (CSF) was positive for HSV by PCR. Late initiation of acyclovir was defined as a delay of >1 day from hospital admission. In total, 184 patients were retrospectively enrolled from January 1991 to December 2002. The median age was 60 years (range: 17-91), and 102 (55.4%) were male. Acyclovir was initiated >1 day after hospital admission in 68 patients (37.0%).
Introduction
Herpes simplex virus (HSV) is the primary cause of viral necrotizing encephalitis in developed countries, and leads to a 70% mortality rate when left untreated [1, 2] . Vidarabine was the first antiviral drug shown to decrease HSV encephalitis (HSE) mortality [3] . Two large clinical trials later showed that outcomes improved significantly when patients took acyclovir [4, 5] , and this drug has since become the standard treatment for HSE. However, the mortality and persistent neurological impairment associated with HSE remain high in developed countries [6, 7] : as many as 53% of patients develop long-term neurological sequelae or die [1] .
One risk factor associated with severe morbidity and mortality related to HSE is delayed initiation of acyclovir [4, 8, 9] . In a study conducted with 93 patients with HSE, Raschilas et al. [8] found that a delay of >2 days from admission to the hospital to initiation of acyclovir was associated with a three-fold increase in poor outcome at 6 months, in comparison with administration before this time. Thankfully, unlike other risk factors associated with mortality and severe morbidity, the time to initiation of therapy can be modified and the prognosis for patients with HSE thereby improved. The aim of this study was to determine the factors associated with late initiation of acyclovir in patients suffering from HSE.
Materials and Methods

Study design and patients
We conducted a retrospective study of 184 patients who had been diagnosed with HSE from 1991 to 1998 and from 1991 to 2002 in the Ile de France and Nord Pas-de-Calais regions of France, respectively. The characteristics and outcomes of the first 93 patients have been described elsewhere [8] . In the current study, we first consulted the records of the virology laboratories at the Hô pital Saint-Vincent de Paul (Ile de France region), Hô pital Calmette, Hô pital de Lens, and PASTEUR CERBA (Nord Pas-de-Calais region). We then consulted the medical records of patients whose cerebrospinal fluid (CSF) was positive for HSV DNA by PCR [10] . We included in our study adult patients, more than 18 years old. We used a standardized checklist to collect data retrospectively from patients' medical records. Data were extracted by one reviewer (FR) in the Ile de France region and by two reviewers (MB and JP) in the Nord Pas-de-Calais region.
Methods
We recorded the age, sex and history of chronic alcohol abuse (positive when it was recorded in the medical records of the patients, and negative when it was not specified) for all recruited patients. We used the Knaus scale to capture the severity of underlying diseases [11] , separating them into four categories: (A) normal health status; (B) moderate infirmity; (C) severe infirmity; and (D) bedridden. Moderate infirmity was defined as the impossibility of work or study, and severe infirmity as the need to have a third person to assist in daily life processes. We used the MacCabe scale to evaluate the prognoses of underlying diseases [12] , segregating outcomes into three categories: (0) no fatal disease; (1) fatal disease with life-expectancy of <5 years; and (2) fatal disease with life-expectancy of <1 year. These categories were determined using knowledge of the prognosis of underlying disease.
We recorded the presence or absence of the following clinical data within the first 24 h of admission: fever (temperature above 37.8°C); focal neurological symptoms, seizures, disorientation, hallucinations, and behavioural changes. These variables were considered to be positive when they were recorded in the medical records of the patients, and negative when they were not specified. The severity of neurological impairment was evaluated using the Glasgow Coma Scale [13] .
We collected computed tomography (CT), magnetic resonance imaging (MRI) and electroencephalographic profiles, as well as CSF leukocyte counts and protein levels, for each patient. We also determined the delay between hospital admission and lumbar puncture, electroencephalography, CT scan, and/or MRI, as well as the time elapsing from hospital admission to acyclovir initiation.
Statistical analysis
Using descriptive analyses, we evaluated the median, minimal and maximal values, and interquartile range (IQR), for each continuous variable. We determined the rate of occurrence of each event to evaluate qualitative variables.
We considered the initiation of acyclovir to be delayed if the drug was administered ‡24 h after hospital admission. In order to establish the factors associated with late initiation of acyclovir, we first performed univariate analyses to determine the association of each variable with late initiation of treatment, using a logistic model with one explicative variable. We measured strength of association using ORs, and assessed the precision of our results using a 95% CI. We used the Wald test to assess the significance of the OR. We evaluated exposures for which the p value was <0.20 in the univariate analysis with a multivariate logistic regression model. Backward stepwise regression procedures were used to develop a final multivariate model that assessed the association of independent factors with late initiation of therapy [14] . A p value <0.05 (two-tailed) was considered to be significant. Statistical analysis was performed using SAS software (SAS 9.1; SAS Institute Inc., Cary, NC, USA).
Results
The median age of the 184 enrolled subjects was 58 years (Table 1) , and 102 (55.4%) of the patients were male. A majority of patients were found to be at stage A on the Knaus scale and at stage 0 on the MacCabe scale. At hospital admission, the median temperature was 39°C (IQR 38.4-39.5). Fifteen per cent of patients were afebrile. Neurological signs and symptoms consisted mainly of language impairment (47.3%), disorientation (43.6%), seizures (36.7%), and behavioural changes (34.9%). The median Glasgow Coma Scale score was 14 (IQR [13] [14] [15] . The median delay between hospital admission and first lumbar puncture was 1 day (IQR 0-1). In initial CSF samples, the median leukocyte count was 83.5/mm 3 (IQR 21-195.5), with lymphocytes predominating, and the median protein level was 0.67 g/L (IQR 0.47-1). The leukocyte count was <10/mm 3 in the initial CSF of 15% of the patients. The median delay between hospital admission and first brain imaging (CT scan or MRI) was day 0 (IQR 0-1). All patients received intravenous acyclovir, after a median delay of 1 day from hospital admission to initiation of acyclovir (IQR 0-3) (Fig. 1) . Among the 181 patients for whom data on vital status were available 6 months after hospital admission, 36 had died (19.9%). The mortality rate was 13% for patients for whom acyclovir was initiated within 1 day of hospital admission vs. 31% for patients for whom acyclovir was initiated >1 day after hospital admission (p <0.02).
According to univariate analysis, patients for whom acyclovir therapy was initiated ‡24 h after hospital admission were more likely to have a history of chronic alcohol abuse (OR 2.5; 95% CI 1.1-5.7), a higher Knaus score (Knaus score C + D vs. Knaus score A and B; OR 2.8; 95% CI 1.2-6.7), and a CSF white cell count <10/mm 3 (OR 2.5; 95% CI 1.0-5.0), and were more frequently afebrile (OR 5.0; 95% CI 1.7-10.0). There was a longer delay between hospital admission and first brain imaging in patients for whom therapy was initiated later than in patients treated early (median, 0 vs. 1; p 0.001) ( Table 2) . Multivariate analysis showed that three factors were independently associated with late initiation of acyclovir: chronic alcohol abuse (p 0.02), high Knaus score (C and D vs. A and B; p 0.007), and delay in the first brain imaging following hospital admission (p <0.001). The risk of late initiation of therapy increased 2.5-fold (95% CI 0.7-5.8) in patients whose CSF white cell counts were <10/mm 3 ; however, this difference was not significant (p 0.17) ( Table 3) .
The proportions of patients enrolled in this study who had a history of chronic alcohol abuse, a high Knaus score, a CSF white cell count <10/mm 3 and delayed CT scan or MRI were 14.7% (n = 27), 14.1% (n = 26), 12.5% (n = 23), and 35.9% (n = 66), respectively. At least one of these risk factors was present in 109 (59.2%) of enrolled patients; two risk factors were present in 29 (15.8%) patients, and three in six (3.3%) patients.
Discussion
Late initiation of acyclovir is the most easily modifiable risk factor for poor outcomes in patients with HSE. To the best of our knowledge, the present study is the first to have evaluated the factors associated with late initiation of acyclovir in a large cohort of patients with HSE. We found, first, that chronic alcohol abuse and a high Knaus score, which depicts the severity of underlying disease, were independently associated with late initiation of therapy. Second, our study demonstrated that delay between hospital admission and initial brain imaging was independently associated with late initiation. Finally, absence of fever and a CSF white cell count <10/mm 3 were more frequent in patients whose treatment was delayed. The 6-month mortality rate for patients with HSE, all of whom were treated with intravenous acyclovir, was 20%. This rate is consistent with HSE mortality rates reported in previous studies [1, 2, 4, 5] . The risk of death increased more than two-fold when acyclovir was initiated ‡1 day after hospital admission.
We found that chronic alcohol abuse and raised Knaus score were independently associated with late initiation of acyclovir. These factors may decrease the probability that clinicians will consider the diagnosis of HSE initially. Indeed, if a patient has known underlying severe disease or a history of alcohol abuse, a physician will probably assume that the observed neurological symptoms are caused by these conditions, rather than considering encephalitis. This study suggests that chronic alcohol abuse and severe underlying disease should not obscure, or lead the clinician away from, the diagnosis of encephalitis. In all patients with neurological symptoms and fever, clinicians should examine the CSF and perform brain imaging in order to detect early HSE or another infectious encephalitis.
Although the absence of fever and CSF white cell counts <10/mm 3 were associated with late initiation of therapy in univariate analysis, there was no statistically significant association in multivariate analysis. This was probably due in part to a lack of statistical power, as the ORs for these associations, especially the low CSF white cell count-late initiation of acyclovir association, did not change between univariate and multivariate analyses. Therefore, doctors should not rule out HSE in the absence of CSF pleocytosis. In this study, 15% of patients with HSE had normal CSF white cell counts on first evaluation. This is a sizeable proportion, and is consistent with results reported in other studies [15] . Moreover, in patients whose leukocyte count is £10/mm 3 , the HSV PCR may be negative when first applied [16] . We suggest starting patients on acyclovir if they have clinical or paraclinical signs of encephalitis and if HSE is suspected, even when the CSF appears normal. We found that a delay in brain imaging was independently associated with late acyclovir initiation. Although CSF examination and MRI or CT scans should be made a priority, queues for these tests should not result in delayed acyclovir initiation for patients with suspected HSE. In particular, brain imaging should delay neither lumbar puncture nor the introduction of acyclovir if HSE is suspected. Brain imaging is now widely used to identify patients in whom lumbar puncture should be avoided. However, patients younger than 60 years, without a seizure within the previous week, and without focal abnormalities upon neurological examination, have been previously identified as good candidates for immediate lumbar puncture without brain imaging [17] . Moreover, in patients with these risk factors and even with mild or moderate mass effects on brain imaging, the risk of lumbar puncture has been found to be negligible [17] . 
